Cardiac Marker Testing Market by Product Type (Reagents and Kits, Instruments), Biomarker Type (Troponin I and T, CK-MB, BNP, Myoglobin, Hs-CRP, Other Biomarkers), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Ischemia), End User (Laboratory Testing, Point-Of-Care-Testing, Others): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00027024 | Pages: 100 | Industry: Pharmaceuticals | Date: Oct 2022 | Type: Global

The market crossed US$ 4.0 billion mark in 2022 and is expected to hit US$ 7.0 billion by 2030, recording a CAGR of 9.0% during the forecast period.

Introduction of novel biomarker tests

Robust research and development on cardiovascular interventions and the introduction of rapid and novel biomarker tests are anticipated to drive the market growth during the forecast period The key market players are investing in the research and development of novel biomarkers for the diagnosis, prognosis, and predictive analysis of cardiovascular disorders. For Instance: in July 2019, Siemens received the U.S. Food and Drug Administration (FDA) approval for high-sensitivity troponin | assays (Tnl) to aid early diagnosis of myocardial infarctions. Additionally, in September 2019, Abbott received U.S. Food and Drug Administration (FDA) approval for its ARCHITECT STAT High Sensitivity Troponin-l blood test. The test is designed to detect heart attacks in quick time, and more accurately than contemporary troponin tests. The introduction of such novel tests for the detection of these biomarkers is anticipated to propel the demand for these tests, and subsequently drive the growth rate of the market during the forecast period.

Within the report, the market is segmented into product type, biomarker type, application, end-user, and geography. On the basis of the product type, the market is bifurcated into reagents and kits, and instruments. On the basis of the biomarker type, the market is segmented into Troponin I and T, CK-MB, BNP, Myoglobin, Hs-CRP, and Other Biomarkers. On the basis of the application, the market is segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and ischemia. Further, by end-user, the market is segmented into laboratory testing, point-of-care-testing, and others. Geographically, the market is segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Get more information on this report :

COVID-19 impact on cardiac marker testing market

The impact of COVID-19 pandemic is expected to remain positive for the cardiac biomarkers testing industry. Due to increase in the number of COVID-19 patient with preexisting medical condition like cardiovascular diseases and among others. As these patients with existing medical conditions like cardiovascular disease suffering from COVID-19 are more heart attack. Furthermore, it was estimated that troponin levels were significantly higher in COVID-19 patients who died or were critically ill. This has led to increase in the demand of cardiac biomarker testing for the patients suffering from COVID-19. Thus, considering all these factors, the global cardiac biomarkers testing market exhibits positive growth during this pandemic and is expected to gain traction in the upcoming years.

The reagents and kits segment showcases the high growth of the cardiac marker testing market.

Based on product type, reagents and kits can be attributed to accounting highest market share during the analysis period. The growing number of cardiac marker testing procedures, accessibility to a wide range of cardiac biomarker reagents and kits, and the growing demand for reliable, specific, and faster detection of cardiovascular diseases at an early stage is driving the segment growth during the forecast period.

Recent strategic developments in the cardiac marker testing market

The cardiac marker testing market has undergone several significant developments, and a few of these have been mentioned below:

  • In April 2021, F. Hoffmann-La Roche Ltd announced the launch of five new applications for their key cardiac biomarkers in combination with their Elecsys technology. These biomarkers have been proven to be successful in managing cardiovascular diseases and can help clinicians to diagnose heart attacks and manage heart failures in patients.
  • In April 2021, Siemens AG. announced that they received CE Mark approval for their point-of-care Atellica VTLiPatient-Side Immunoassay Analyzer, a high sensitivity troponin I test. The approved device detects protein biomarkers for acute myocardial infarction.

The cardiac marker testing market is driven by several players by implementing strategic activities such as Roche Diagnostics Ltd, Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation, Ortho Clinical Diagnostics, Randox Laboratories Ltd.,  bioMérieux SA, LSI Medience Corporation, DiaSorin S.p.A., and Bio-Rad Laboratories, Inc. are among the prominent players operating in the market.

Target audience for the report:

  • Cardiac marker testing providers
  • Cardiology-related associations, organizations, forums, and alliances
  • Government bodies, such as regulating authorities
  • Venture capitalists, private equity firms, and start-up companies
  • End users of Cardiac marker
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Product Type:
    • Reagents and Kits
    •  Instruments
  • Biomarker Type:
    • Troponin I and T
    • CK-MB
    • BNP
    •  Myoglobin
    • Hs-CRP
    • Other Biomarkers
  • Application:
    • Myocardial Infarction
    • Congestive Heart Failure
    • Acute Coronary Syndrome
    • Atherosclerosis
    • Ischemia
  • End User:
    • Laboratory Testing
    • Point-Of-Care-Testing
    • Others
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
  • Roche Diagnostics Ltd
  •  Abbott Laboratories
  •  Siemens Healthineers AG
  •  Danaher Corporation
  •  Ortho Clinical Diagnostics
  •  Randox laboratories Ltd.
  •  bioMérieux SA
  •  LSI Medience Corporation
  •  DiaSorin S.p.A.
  •  Bio-Rad Laboratories, Inc.

The List of Companies
- Roche Diagnostics Ltd
- Abbott Laboratories
- Siemens Healthineers AG
- Danaher Corporation
- Ortho Clinical Diagnostics
- Randox laboratories Ltd.
- bioM?rieux SA
- LSI Medience Corporation
- DiaSorin S.p.A.
- Bio-Rad Laboratories, Inc.

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$1500
Site License
$2500
Enterprise License
$3500